Truist Financial Maintains a Buy Rating on Autolus Therapeutics (AUTL)

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best strong buy penny stocks to buy now. On June 17, Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) without a price target.

A laboratory technician carefully studying a microscope with a biopharmaceutical product inside.

In other news, Autolus Therapeutics plc (NASDAQ:AUTL) announced on July 21 that the European Commission (EC) granted marketing authorization for AUCATZYL for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Management reported that the EC approval was based on the results of the FELIX study, which is “an open-label, multi-centre, single arm study in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia”.

Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer and focuses on chimeric antigen receptor (CAR) T cell therapy.

The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.